SAN DIEGO, Jan. 23, 2017 /PRNewswire/ -- ResMed Inc.
(NYSE: RMD) today announced results for its quarter ended December 31, 2016. Revenue for the
quarter was $530.4 million, a 17 percent increase compared to the same period of the prior year.
Excluding the contribution from the Brightree business acquired in April 2016, revenue for the
quarter was $496.6 million, a 9 percent increase.
"We had a strong quarter with 18 percent constant currency revenue growth led by solid growth in our Brightree software
offerings and global device sales," said Mick Farrell, ResMed's chief executive officer. "We
continue to pioneer game-changing products and create value with our solutions. This quarter we announced: FDA clearance for the
world's smallest travel CPAP; the creation of SleepScore Labs to focus on consumer sleep wellness; reaching the milestone of one
billion nights of sleep data; and new research demonstrating that the use of myAir™ significantly improves patient adherence to
sleep therapy in Europe."
Farrell concluded, "We are focused on our goal of changing the lives of 20 million patients by 2020 and we continue to lead
the industry through an exciting pipeline of new products and connected care solutions that improve patient outcomes, create
efficiencies for our homecare customers, and help physicians and providers better manage chronic disease and lower healthcare
costs."
Analysis of second quarter results
Second quarter revenue in the Americas was $326.8 million, a 21 percent increase over the
same period of the prior year. This included Brightree revenue of $33.8 million. Excluding
Brightree, revenue in the Americas was $293.0 million, a 9 percent increase over the prior year.
Revenue in combined EMEA and APAC was $203.6 million, an increase of 13 percent on a constant
currency basis, compared to the same period of the prior year.
Gross margin in the second quarter was 58.3 percent, higher than the prior year's quarter gross margin of 58.1 percent,
excluding the prior year release of $2.4 million in accrued expenses associated with the SERVE-HF
field safety notice. The improvement in gross margin compared to prior year's quarter was due to manufacturing and procurement
efficiencies and an incremental contribution from the Brightree acquisition, partly offset by changes in product mix and declines
in average selling prices.
Income from operations for the quarter was $96.9 million, a 10 percent decline compared with the
quarter ended December 31, 2015. Non-GAAP income from operations for the quarter was $131.6 million, a 13 percent increase compared to the same period of the prior year.
Selling, general and administrative expenses were $139.3 million, an 18 percent increase over
the same period in the prior year, also an 18 percent increase on a constant currency basis. SG&A expenses increased to 26.3
percent of revenue in the quarter, compared with 26.0 percent reported in the quarter ended December
31, 2015.
Research and development expenses were $38.2 million, or 7.2 percent of revenue. R&D
expenses increased by 32 percent compared with the same period last year, or a 28 percent increase on a constant currency
basis.
Amortization of acquired intangible assets was $11.7 million during the quarter, an increase of
$7.3 million compared with the same period last year. The increase in amortization of acquired
intangible assets was primarily due to the amortization expense associated with the Brightree and Inova acquisitions.
Stock-based compensation costs incurred during the quarter of $10.8 million consisted of expenses
associated with employee equity grants, and our employee stock purchase plan.
Net income for the quarter was $76.7 million, a 20 percent decrease compared to the same period
of the prior year. Non-GAAP net income was $103.3 million, a 1 percent increase compared to the
prior year.
Non-GAAP measures adjust for amortization of acquired intangibles, litigation settlement expenses, acquisition related
expenses associated with additional contingent consideration on recent acquisitions and restructuring expenses.
GAAP diluted earnings per share for the quarter decreased 21 percent to $0.54. Non-GAAP
diluted earnings per share of $0.73 were consistent with the same period of the prior
year.
Cash flow from operations for the quarter was $119.9 million compared to net income in the
current quarter of $76.7 million.
Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.33 per
share. The dividend will have a record date of February 9, 2017, payable on March 16, 2017. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the
New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an
equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between
CDIs and NYSE shares. The ex-dividend date will be February 8, 2017 for common stock holders and
for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer
processing conversions between its common stock and CDI registers from February 7, 2017 through
February 9, 2017 inclusive.
Webcast details
ResMed will discuss its financial and business results and outlook on its webcast at 1:30
p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at
investor.resmed.com. Please go to this section of the website and click on the icon for the "Q2 2017
earnings webcast" to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed's
website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours
after the call by dialing 855-859-2056 (U.S.) and +1 404-537-3406 (international) and entering a passcode of 40778584. The
telephone replay will be available until February 6, 2017.
About ResMed
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications
that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.
ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong
team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the
impact of chronic disease, and saving healthcare costs in more than 100 countries.
Safe harbor statement
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by
the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed's
projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its
products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to
materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are
discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not
undertake to update its forward-looking statements.
|
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Statements of Income (Unaudited)
(In thousands, except per share data)
|
|
|
Three Months Ended
December 31,
|
Six Months Ended
December 31,
|
|
2016
|
2015
|
2016
|
2015
|
|
|
|
|
|
|
Net revenue
|
$530,397
|
$454,540
|
$995,846
|
$866,187
|
|
Cost of sales
|
221,326
|
190,433
|
412,522
|
363,461
|
|
Astral field safety notification expenses (1)
|
-
|
-
|
5,070
|
-
|
|
SERVE-HF accrual release (1)
|
-
|
(2,402)
|
-
|
(2,402)
|
|
Gross profit
|
309,071
|
266,509
|
578,254
|
505,128
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
Selling, general and administrative
|
139,307
|
118,219
|
268,158
|
229,314
|
|
Research and development
|
38,190
|
28,970
|
72,637
|
56,162
|
|
Restructuring expenses (1)
|
4,413
|
6,914
|
4,413
|
6,914
|
|
Litigation settlement expenses (1)
|
8,500
|
-
|
8,500
|
-
|
|
Acquisition related expenses (1)
|
10,076
|
-
|
10,076
|
-
|
|
Amortization of acquired intangible assets (1)
|
11,690
|
4,429
|
23,431
|
6,736
|
|
Total operating expenses
|
212,176
|
158,532
|
387,215
|
299,126
|
|
Income from operations (1)
|
96,895
|
107,977
|
191,039
|
206,002
|
|
|
|
|
|
|
Other income (expenses), net:
|
|
|
|
|
|
Interest income (expense), net
|
(2,437)
|
2,476
|
(4,929)
|
5,898
|
|
Other, net
|
1,749
|
3,242
|
3,021
|
1,239
|
|
Total other income (expenses), net
|
(688)
|
5,718
|
(1,908)
|
7,137
|
|
Income before income taxes
|
96,207
|
113,695
|
189,131
|
213,139
|
|
Income taxes excluding ASU 2016-09 (2)
|
19,439
|
23,178
|
38,735
|
42,220
|
|
Income taxes relating to ASU 2016-09 (2)
|
25
|
(5,059)
|
(2,453)
|
(7,574)
|
|
Total income taxes
|
19,464
|
18,119
|
36,282
|
34,646
|
|
Net income (1)
|
$76,743
|
$95,576
|
$152,849
|
$178,493
|
|
|
|
|
|
|
Basic earnings per share
|
$0.54
|
$0.68
|
$1.08
|
$1.27
|
|
Diluted earnings per share
|
$0.54
|
$0.68
|
$1.08
|
$1.26
|
|
Non-GAAP diluted earnings per share (1)
|
$0.73
|
$0.73
|
$1.34
|
$1.32
|
|
|
|
|
|
|
Basic shares outstanding
|
141,310
|
139,926
|
141,048
|
140,118
|
|
Diluted shares outstanding
|
142,097
|
141,423
|
141,982
|
141,837
|
|
|
|
|
|
|
|
|
(1)
|
See the reconciliation of non-GAAP financial measures in the table at
the end of the press release.
|
|
|
|
(2)
|
As a result of the adoption of ASU 2016-09 "Improvements to
Employee Share-Based Payment Accounting" during the quarter ended June 30, 2016 we now recognize an income tax impact
relating to share-based payment transactions. The income taxes for the three and six months ended December 31, 2015 have
been restated to reflect the adoption of the standard as the benefit was previously recorded as a reduction to Additional
Capital.
|
|
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited - In thousands)
|
|
|
December 31,
|
June 30,
|
|
2016
|
2016
|
|
ASSETS:
|
|
|
|
Current assets:
|
|
|
|
Cash and cash equivalents
|
$788,146
|
$731,434
|
|
Accounts receivable, net
|
383,992
|
382,086
|
|
Inventories
|
253,108
|
224,456
|
|
Prepayments and other current assets
|
95,028
|
81,743
|
|
Total current assets
|
1,520,274
|
1,419,719
|
|
Property, plant and equipment, net
|
375,928
|
384,276
|
|
Goodwill
|
1,046,304
|
1,059,245
|
|
Other intangibles, net
|
275,422
|
299,808
|
|
Deferred income taxes and other non-current assets
|
104,642
|
93,657
|
|
Total non-current assets
|
1,802,296
|
1,836,986
|
|
Total assets
|
$3,322,570
|
$3,256,705
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
|
|
|
Current liabilities:
|
|
|
|
Accounts payable
|
$94,100
|
$92,571
|
|
Accrued expenses
|
216,225
|
156,805
|
|
Deferred revenue
|
46,389
|
50,009
|
|
Income taxes payable
|
25,869
|
39,166
|
|
Short-term debt
|
299,812
|
299,438
|
|
Total current liabilities
|
682,395
|
637,989
|
|
Non-current liabilities:
|
|
|
|
Deferred income taxes
|
13,789
|
9,061
|
|
Deferred revenue
|
46,682
|
40,281
|
|
Other long term liabilities
|
864
|
1,211
|
|
Long-term debt
|
868,690
|
873,332
|
|
Total non-current liabilities
|
930,025
|
923,885
|
|
Total liabilities
|
1,612,420
|
1,561,874
|
|
STOCKHOLDERS' EQUITY:
|
|
|
|
Common stock
|
566
|
563
|
|
Additional paid-in capital
|
1,335,895
|
1,303,238
|
|
Retained earnings
|
2,220,283
|
2,160,299
|
|
Treasury stock
|
(1,546,611)
|
(1,546,611)
|
|
Accumulated other comprehensive income
|
(299,983)
|
(222,658)
|
|
Total stockholders' equity
|
$1,710,150
|
$1,694,831
|
|
|
|
|
Total liabilities and stockholders' equity
|
$3,322,570
|
$3,256,705
|
|
|
|
|
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited - In
thousands)
|
|
|
Six Months Ended
December 31,
|
|
2016
|
2015
|
|
Cash flows from operating activities:
|
|
|
|
Net income
|
$152,849
|
$178,493
|
|
Adjustment to reconcile net income to cash provided by operating
activities:
|
|
|
|
Depreciation and amortization
|
55,504
|
39,920
|
|
Impairment of long-lived asset
|
-
|
2,815
|
|
Stock-based compensation costs
|
22,802
|
23,841
|
|
Changes in fair value of business combination contingent
consideration
|
10,076
|
-
|
|
Impairment of cost-method investments
|
206
|
750
|
|
Changes in operating assets and liabilities, net of effect of
acquisitions:
|
|
|
|
Accounts receivable, net
|
(7,080)
|
24,533
|
|
Inventories, net
|
(36,104)
|
8,751
|
|
Prepaid expenses, net deferred income taxes and other current
assets
|
(15,197)
|
14,398
|
|
Accounts payable, accrued expenses and other
|
23,086
|
(13,279)
|
|
Net cash provided by operating activities
|
206,142
|
280,222
|
|
Cash flows from investing activities:
|
|
|
|
Purchases of property, plant and equipment
|
(29,247)
|
(30,934)
|
|
Patent registration costs
|
(4,603)
|
(4,902)
|
|
Business acquisitions, net of cash acquired
|
(3,184)
|
(152,118)
|
|
Investments in cost-method investments
|
(3,867)
|
(7,582)
|
|
Proceeds / (Payments) on maturity of foreign currency contracts
|
8,209
|
(28,326)
|
|
Net cash used in investing activities
|
(32,692)
|
(223,862)
|
|
Cash flows from financing activities:
|
|
|
|
Proceeds from issuance of common stock, net
|
9,816
|
8,066
|
|
Purchases of treasury stock
|
-
|
(102,058)
|
|
Payment of business combination contingent consideration
|
-
|
(1,120)
|
|
Proceeds from borrowings, net of borrowing costs
|
75,000
|
200,000
|
|
Repayment of borrowings
|
(80,000)
|
(100,160)
|
|
Dividends paid
|
(92,865)
|
(84,054)
|
|
Net cash (used in) / provided by financing activities
|
(88,049)
|
(79,326)
|
|
Effect of exchange rate changes on cash
|
(28,689)
|
(35,479)
|
|
Net increase / (decrease) in cash and cash equivalents
|
56,712
|
(58,445)
|
|
Cash and cash equivalents at beginning of period
|
731,434
|
717,249
|
|
Cash and cash equivalents at end of period
|
$788,146
|
$658,804
|
|
Reconciliation of Non-GAAP Financial Measures (Unaudited)
(In US$ thousands, except share and per share data)
|
|
|
The measure, "non-GAAP income from operations" is reconciled with GAAP
income from operations below:
|
|
|
Three Months Ended
December 31
|
Six Months Ended
December 31,
|
|
2016
|
2015
|
2016
|
2015
|
|
GAAP income from operations
|
$96,895
|
$107,977
|
$191,039
|
$206,002
|
|
SERVE-HF accrual release (A)
|
-
|
(2,402)
|
-
|
(2,402)
|
|
Astral battery field safety notification expenses
(A)
|
-
|
-
|
5,070
|
-
|
|
Restructuring expenses (A)
|
4,413
|
6,914
|
4,413
|
6,914
|
|
Litigation settlement expenses (A)
|
8,500
|
-
|
8,500
|
-
|
|
Acquisition related expenses (A)
|
10,076
|
-
|
10,076
|
-
|
|
Amortization of acquired intangible assets (A)
|
11,690
|
4,429
|
23,431
|
6,736
|
|
Non-GAAP income from operations
|
$131,574
|
$116,918
|
$242,529
|
$217,250
|
|
|
The measures "non-GAAP net income" and "non-GAAP diluted earnings per
share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
|
|
|
Three Months Ended
December 31,
|
Six Months Ended
December 31,
|
|
2016
|
2015
|
2016
|
2015
|
|
GAAP net income
|
$76,743
|
$95,576
|
$152,849
|
$178,493
|
|
SERVE-HF accrual release, net of tax (A)
|
-
|
(1,682)
|
-
|
(1,682)
|
|
Astral battery field safety notification expenses
(A)
|
-
|
-
|
3,549
|
-
|
|
Restructuring expenses, net of tax (A)
|
3,085
|
5,204
|
3,085
|
5,204
|
|
Litigation settlement expenses, net of tax (A)
|
5,392
|
-
|
5,392
|
-
|
|
Acquisition related expenses (A)
|
10,076
|
-
|
10,076
|
-
|
|
Amortization of acquired intangible assets, net of tax
(A)
|
7,968
|
3,439
|
15,975
|
5,156
|
|
Non-GAAP net income (A)
|
$103,264
|
$102,537
|
$190,926
|
$187,171
|
|
Diluted shares outstanding
|
142,097
|
141,423
|
141,982
|
141,837
|
|
GAAP diluted earnings per share
|
$0.54
|
$0.68
|
$1.08
|
$1.26
|
|
Non-GAAP diluted earnings per share (A)
|
$0.73
|
$0.73
|
$1.34
|
$1.32
|
|
(A)
|
ResMed adjusts for the impact of the Astral battery field safety
notification expenses, release of SERVE-HF accrual, restructuring expenses, litigation settlement expenses, acquisition
related expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes
investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating
performance.
|
|
|
|
ResMed believes that non-GAAP diluted earnings per share is an additional
measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP
information internally in planning, forecasting, and evaluating the results of operations in the current period and in
comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed's
performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to
supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures,
non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included
under GAAP.
|
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/resmed-inc-announces-results-for-the-second-quarter-of-fiscal-year-2017-300394955.html
SOURCE ResMed Inc.